On May 1, 2023 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, reported that it will report first quarter financial results on Tuesday, May 9, 2023, after the close of U.S. markets (Press release, CytomX Therapeutics, MAY 1, 2023, View Source [SID1234630767]). Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at View Source Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.

On May 1, 2023 CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, reported that two abstracts have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place June 2-6, 2023 in Chicago, IL (Press release, CTI BioPharma, MAY 1, 2023, View Source [SID1234630766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are as follows:

Title: Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis
Abstract #: 7018
Presenter: Helen Ajufo, M.D., Memorial Sloan Kettering Cancer Center
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Monday, June 5, 2023, 8:00 – 11:00 a.m. CT
Location: Hall A, Poster #148
Poster discussion: In addition to the poster presentation, Dr. Ajufo will host a poster discussion session on Monday, June 5, 2023 from 11:30 a.m. – 1:00 p.m. CT in Room E450.

Title: Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias
Abstract #: 7068
Presenter: Dr. Prithviraj Bose, M.D., The University of Texas MD Anderson Cancer Center
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: Monday, June 5, 2023, 8:00 – 11:00 a.m. CT
Location: Hall A, Poster #198

On May 1, 2023 CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, reported that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets (Press release, CTI BioPharma, MAY 1, 2023, View Source [SID1234630765]). Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in advance using the link provided in the event listing. The Company suggests participants log in 15 minutes in advance of the event.

On May 1, 2023 Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS) reported its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023 (Press release, Coherus Biosciences, MAY 1, 2023, View Source/news-releases/news-release-details/coherus-biosciences-report-first-quarter-2023-financial-results" target="_blank" title="View Source/news-releases/news-release-details/coherus-biosciences-report-first-quarter-2023-financial-results" rel="nofollow">View Source [SID1234630764]). Starting at 5:00 pm ET on May 8, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A replay of the webcast will be available on View Source following the conclusion of the live conference call.

Conference Call Information
When: Monday, May 8th, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI12e6d284dae8440e91891f2cef4f2097

Webcast: View Source

The press release with the first quarter financial results and related materials will be available at View Source prior to the start of the conference call.

A live and archived webcast will be available on the "Investors" section of the Coherus website at View Source.

Please dial-in 15 minutes early to ensure a timely connection to the call.

On May 1, 2023 Celularity Inc. (Nasdaq: CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, reported that Adrian Kilcoyne, M.D., M.P.H., M.B.A., Celularity’s Chief Medical Officer, will present data at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy, which will be held May 16-20th in Los Angeles (Press release, Celularity, MAY 1, 2023, View Source [SID1234630755]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The title of Dr. Kilcoyne’s abstract is, "Placental-Derived Mesenchymal-Like Adherent Stromal Cell (MLASC) Therapy Results in Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn’s Disease."

"We have had a long interest in the role of cell therapy in autoimmune diseases and look forward to presenting our MLASC data in Crohn’s disease at the upcoming ASGCT (Free ASGCT Whitepaper) annual meeting," said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder.

"In light of our clinical observations described in a previous release, these data provide a possible mechanism of action leverageable in a broad range of immune-mediated diseases and will help guide the investment decision to progress our novel genetically modified allogeneic placental-derived MLASC, APPL-01, in Crohn’s disease. We believe this cell therapy candidate could make a significant difference as a therapeutic option for patients. Celularity’s unique technology platform is grounded in our use of the post-partum placenta as the source of cells and biomaterials, enabling independent but complementary product opportunities in cellular and regenerative medicine. We’re moving forward with confidence regarding the potential therapeutic benefits of MLASCs as we advance the development of therapeutic options for patients," said Hariri.

About the Poster Presentation

Thursday, May 18, 12:00 noon – 2:00 pm Pacific Time, Board No. 1111

Placental-Derived Mesenchymal-Like Adherent Stromal Cell (MLASC) Therapy Results in Alterations in Gene and Protein Signatures Associated with Inflammation and Fistula Formation in Patients with Crohn’s Disease

A. Kilcoyne, S. Koppisetti, B. Glover, W. VanDerTouw, C. Daly, V. Jankovic, R. Hariri. Celularity, Florham Park, NJ, Regeneron, Tarrytown, NY